NCT05218902

A Study of Azacitidine in Participants With International Prognostic Scoring System (IPSS) Intermediate-2 and High-risk Myelodysplastic Syndromes (MDS), or Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML)

A Prospective/Retrospective Non-Interventional Study of Vidaza® (Azacitidine) in Patients With International Prognostic Scoring System (IPSS) Intermediate-2 and High-risk Myelodysplastic Syndromes, or Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia With 20-30% Blasts and Multi-lineage Dysplasia in China

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 290 (actual)
• Sponsor: Bristol-Myers Squibb · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to assess the safety and effectiveness in the real-world setting among participants who are treated with Azacitidine in accordance with the China Product Label.

Detailed description

This study will have participants both enrolled retrospectively and prospectively for azacitidine (AZA) treatment.

Conditions

• Myelodysplastic Syndromes
• Leukemia, Myelomonocytic, Chronic
• Leukemia, Myeloid, Acute

Timeline

• Start date: 2022-02-25
• Primary completion: 2023-03-20
• Completion: 2023-03-20
• First posted: 2022-02-01
• Last updated: 2023-05-31

Locations

1 site across 1 country: China